Global Pediatric Vaccine Market - 2024-2031

Global Pediatric Vaccine Market - 2024-2031

Global Pediatric Vaccines market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Vaccinations specifically designed for pediatric patients are essential for shielding young patients from a variety of potentially dangerous illnesses. These vaccinations aid in a child's body's development of immunity against particular illnesses. A child's body is ready to combat the virus or bacterium when they are exposed to it later in life.

Pediatric vaccines include Diphtheria, tetanus, and whooping cough (pertussis) (DTaP) Haemophilus influenzae type b (Hib) Measles, mumps, rubella (MMR) Polio (IPV) among others.

Market Dynamics: Drivers & Restraints

Rising incidence of chronic and infectious diseases

The rising incidence of chronic and infectious diseases is a significant driver for the growth of the global pediatric vaccine market. Rising infections create an awareness and concern among individuals to control these infections. This increases demand for pediatrics vaccinations to avoid infections for the rest of their lives.

There is an increased infection rate among individuals who are suffering from infections. For instance according to the World Health Organization in 2024, it was reported that in 2022, there were an estimated 1,36,000 measles deaths globally, mostly among unvaccinated or under-vaccinated children under the age of 5 years. This creates an awareness among unvaccinated individuals.

Additionally, the National Foundation for Infectious Diseases stated that Influenza (flu) is a serious illness that leads to thousands of hospitalizations, most in children younger than 5 years of age. It is estimated that an average of 20,000 children under the age of 5 are hospitalized due to flu complications each year. Thus, the above factors are expected to drive the market growth.

Limited availability of healthcare services

Access to immunization clinics and healthcare professionals qualified to deliver vaccines might be challenging in rural or isolated locations with inadequate healthcare infrastructure. Children in such areas may have experienced decreased immunization rates as a result. Vaccine delivery programs may encounter difficulties due to a shortage of medical professionals with the necessary training, such as nurses and doctors, to provide immunizations because of which immunization schedules for children may be delayed or disrupted.

Segment Analysis

The global pediatric vaccine market is segmented based on disease type, vaccine type, technology and region.

Multivalent Vaccines segment is expected to dominate the market growth

Broader-spectrum multivalent vaccinations have the potential to enhance herd immunity, hence reducing disease transmission and outbreaks in communities. In a single dose, multivalent vaccinations protect against several diseases. As a result, a child requires fewer injections overall, which lessens the pain and worry related to vaccines. This raises vaccine completion rates and adherence to immunization schedules.

They offer defense against a greater variety of disease-causing strains or serotypes. This is especially important for illnesses like influenza when new strains appear all the time. For instance, compared to a monovalent vaccine, the hexavalent vaccine provides more extensive immunity by protecting against six distinct rotavirus strains. It may be less expensive to use a multivalent vaccine than to give several monovalent doses. Parents and healthcare systems can both save money as a result of this.

Geographical Analysis

North America is expected to hold a significant position in the pediatric vaccine market share

North America accounted for the largest revenue share in 2023. North America has a well-established and innovative pharmaceutical industry that heavily invests in research and development of new and improved vaccines, including pediatric options. Public health initiatives that support childhood immunization are well-established in many North American nations. This implies that there is a wider market for pediatric vaccines to target.

The presence of a large number of major market players in the region is also expected to contribute to the growth of the market in the region. Pharmaceutical companies are manufacturing a variety of vaccinations that increase the availability to children in every remote area.

For instance, on April 27, 2023, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for PREVNAR 20 (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcal) serotypes contained in the vaccine in infants and children six weeks through 17 years of age, and for the prevention of otitis media in infants six weeks through five years of age caused by the original seven serotypes contained in PREVNAR.

Additionally, in August 2023, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for the ABRYSVO (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. Thus, the above factors are expected to hold the region in the dominant market share during the forecast period.

COVID-19 Impact Analysis

COVID-19 has shown a negative impact on the pediatric vaccine market growth. Regular pediatric vaccines were delayed as a result of lockdowns and worries about COVID-19 contamination. Some pediatric vaccines experienced a decrease in demand as a result of this. False information about COVID-19 immunizations has made people more reluctant to get immunized overall, including children. Routine childhood vaccinations may have been delayed as a result of the pandemic response's overwhelming strain on healthcare services.

Market Segmentation

By Disease Type
• Infectious Diseases
Polio
Influenza
Measles
Mumps
Rubella (MMR)
Pneumococcal disease
Human papillomavirus
Hepatitis
Others
• Allergies

By Vaccine Type
• Monovalent Vaccines
• Multivalent Vaccines

By Technology
• Live attenuated Vaccines
• Inactivated Vaccines
• Sub-unit Vaccines
• Toxoid Vaccines
• Conjugate Vaccines
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Pfizer Inc., Sanofi SA, Merck & Co., Takeda Pharmaceuticals, Indian Immunological limited, Bharat Biotech, Panacea Biotec, Sinovac Biotech, AstraZeneca, and Novartis AG among others.

Why Purchase the Report??
• To visualize the global pediatric vaccines market segmentation based on disease type, vaccine type, technology and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pediatric vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global pediatric vaccines market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies